Form 4: Eli Lilly Director Ralph Alvarez Acquires Shares Through Compensation Deferral Plan

Eli Lilly & Co. Director Ralph Alvarez acquired 14.55 shares of common stock on June 16, 2025, as part of a compensation deferral plan, increasing his total beneficial ownership to 54,979.164 shares.

Summary

• Ralph Alvarez, a Director at Eli Lilly & Co. (LLY), acquired 14.55 shares of common stock.
• The transaction occurred on June 16, 2025, with each share valued at $807.58.
• These shares were acquired as part of the Lilly Directors' Deferral Plan, where they were deferred in lieu of cash compensation.
• The shares will be settled as common stock following Mr. Alvarez's separation from service.
• Following this transaction, Mr. Alvarez's total beneficial ownership in Eli Lilly & Co. stands at 54,979.164 shares.

Sentiment

Score: 6

Explanation: The acquisition of shares by a director, even if part of a compensation plan, is generally a neutral to slightly positive signal as it increases their stake and aligns their interests with shareholders. The small size of the transaction prevents a higher score.

Positives

• A director increasing their stake, even through a compensation plan, can signal continued alignment with shareholder interests.
• The use of a deferral plan indicates a long-term commitment by the director to the company's equity.

Negatives

• The acquisition amount (14.55 shares) is relatively small in the context of the company's overall market capitalization and the director's total holdings, limiting its significance as a strong positive signal.

Future Outlook

The document does not provide any forward-looking statements or guidance beyond the settlement terms of the deferred shares.

Management Comments

• At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide broader industry context or trends. It reflects a standard compensation practice for directors in the pharmaceutical industry, where equity-based compensation is common to align interests with shareholders.

Comparison to Industry Standards

• This transaction is a standard practice for director compensation in large publicly traded companies, including those in the pharmaceutical sector. Many companies offer directors the option to defer cash compensation into equity units, aligning their long-term interests with the company's performance. Specific comparable companies or projects are not relevant for this type of routine insider transaction.

Related Party Transactions

• The acquisition of shares by Director Ralph Alvarez from Eli Lilly & Co. as part of a compensation deferral plan constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The transaction slightly increases the director's ownership stake, potentially reinforcing alignment of interests.

Next Steps

• The acquired stock units will be settled in shares of common stock following the reporting person's separation from service.

Key Dates

Keywords

Eli Lilly, LLY, Ralph Alvarez, Director, Insider Trading, Form 4, SEC Filing, Stock Acquisition, Compensation Plan, Share Ownership, Pharmaceuticals